Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;105:766-769
doi: 10.1161/hc0602.103396
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yasukawa, K.
Right arrow Articles by Rowley, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasukawa, K.
Right arrow Articles by Rowley, A. H.
Related Collections
Right arrow Growth factors/cytokines

(Circulation. 2002;105:766.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Systemic Production of Vascular Endothelial Growth Factor and fms-Like Tyrosine Kinase-1 Receptor in Acute Kawasaki Disease

Kumi Yasukawa, MD; Masaru Terai, MD; Stanford T. Shulman, MD; Tetsuya Toyozaki, MD; Shigehiro Yajima, MD; Yoichi Kohno, MD; Anne H. Rowley, MD

From the Departments of Pediatrics, Kawasaki Seitetsu Hospital (K.Y.), Chiba, Japan, and Takayama Red Cross Hospital (S.Y.), Gifu, Japan; Department of Pediatrics (K.Y., M.T., Y.K.) and Institute of Pulmonary Cancer Research (T.T.), Chiba University School of Medicine, Chiba, Japan; and Departments of Pediatrics (S.T.S., A.H.R.) and Microbiology and Immunology (A.H.R.), Northwestern University Medical School, Chicago, Ill.

Correspondence to Masaru Terai, MD, Department of Pediatrics, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan. E-mail terai{at}med.m.chiba-u.ac.jp

Background Increased vascular permeability is an important event during the initial process of Kawasaki disease (KD). One potential responsible candidate for the induction of vascular hyperpermeability is vascular endothelial growth factor (VEGF).

Methods and Results We investigated the expression of VEGF and its receptors (flt-1, KDR) in acute KD tissues at 7 days to 5 weeks of illness. Neuropilin-1, which enhances the binding of VEGF165 to KDR, was also studied. Abundant expression of VEGF and flt-1 was documented immunohistochemically in many organs from acute KD, including heart and lung. VEGF and flt-1 were colocalized in all vessels that showed edema. These molecules resided in endothelium and vascular media and also in migrating smooth muscle cells in neointima and infiltrating macrophages. Compared with controls, coronary vessels of acute KD had upregulation of VEGF and flt-1 but not KDR or neuropilin-1. KDR was expressed by vessels at 7 days of illness but not later in the illness. Plasma proteins were more extensively bound to the extracellular matrix in coronary vessels in acute KD than controls. Furthermore, elevation of serum VEGF levels was correlated with low serum albumin in acute KD (n=220, r=-0.53, P<0.001).

Conclusions These findings suggest that VEGF and flt-1 are upregulated in blood vessels in many organs of acute KD. Expression of KDR was limited to the early stage of acute KD. The roles of VEGF in acute KD may involve promotion of vascular permeability and macrophage activation. Low serum albumin may indicate overproduction of VEGF in acute KD.


Key Words: Kawasaki disease • growth substances • receptors




This article has been cited by other articles:


Home page
PediatricsHome page
J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al.
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
Pediatrics, December 1, 2004; 114(6): 1708 - 1733.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al.
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
Circulation, October 26, 2004; 110(17): 2747 - 2771.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
Y Uziel, P J Hashkes, E Kassem, G Gottesman, and B Wolach
"Unresolving pneumonia" as the main manifestation of atypical Kawasaki disease
Arch. Dis. Child., October 1, 2003; 88(10): 940 - 942.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Terai, T. Honda, K. Yasukawa, K. Higashi, H. Hamada, and Y. Kohno
Prognostic Impact of Vascular Leakage in Acute Kawasaki Disease
Circulation, July 22, 2003; 108(3): 325 - 330.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Minami, D. J. Donovan, J. C. Tsai, R. D. Rosenberg, and W. C. Aird
Differential regulation of the von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine phosphoribosyltransferase-targeted mice
Blood, December 1, 2002; 100(12): 4019 - 4025.
[Abstract] [Full Text] [PDF]